Morning Briefing
Summaries of health policy coverage from major news organizations
MRNA Boosters May Give Longer-Lasting Protection Than 2 Shots
Reuters: Protection May Last Longer After Vaccine Booster Dose
Protection against COVID-19 from an mRNA vaccine - either the Moderna or Pfizer/BioNTech shots - may last longer after the booster dose than after the original two-shot regimen, researchers speculated based on the results of a small new study. They measured vaccine responses before and after the boosters in 33 healthy middle-aged adults who had received their second doses an average of nine months earlier. Before the boosters, their antibody levels had decreased about 10-fold from levels early after their second dose. By 6 to 10 days after the booster, their antibody levels had climbed 25-fold and were five times higher than after two doses of the vaccine, according to a report posted on Sunday on medRxiv ahead of peer review. In the volunteers who had COVID-19 before being vaccinated, antibody levels after the booster were 50-fold higher than after their infections. "Because these antibody levels are so robust, the booster could potentially give us protection for a longer duration than what we saw for two doses of the vaccine," study coauthor Alexis Demonbreun of Northwestern University Feinberg School of Medicine in Chicago, said in a statement. (Lapid, 11/22)
Reuters: Experimental Chewing Gum Reduces Virus In Saliva
An experimental chewing gum containing a protein that "traps" coronavirus particles could limit the amount of virus in saliva and help curb transmission when infected people are talking, breathing or coughing, researchers believe. The gum contains copies of the ACE2 protein found on cell surfaces, which the virus uses as a gateway to break into cells and infect them. In test-tube experiments using saliva and swab samples from infected individuals, virus particles attached themselves to the ACE2 "receptors" in the chewing gum. As a result, the viral load in the samples fell by more than 95%, the research team from the University of Pennsylvania reported in Molecular Therapy. The gum feels and tastes like conventional chewing gum, can be stored for years at normal temperatures, and chewing it does not damage the ACE2 protein molecules, the researchers said. Using gum to reduce viral loads in saliva , they suggest, would add to the benefit of vaccines and would be particularly useful in countries where vaccines are not yet available or affordable. (Lapid, 11/22)
On "active grandparents" and AI in health care —
Stat: New Research Explores The ‘Active Grandparent Hypothesis’ And Evolution
Evolutionary biologist Daniel Lieberman takes the long view of physical activity. His name has been connected to running and human evolution ever since his seminal Nature study “Endurance running and the evolution of Homo” appeared in 2004, and he’s been linked to barefoot running in particular after a 2010 study, also in Nature, explored the impact of modern padded running shoes on our strides. Lieberman’s research interests range wider than running, spanning physical activity across the evolutionary history of what moves humans, in the industrialized world and in traditional hunter-gatherer societies. In a new review published Monday in PNAS, Lieberman and his Harvard co-authors grapple with the “active grandparent hypothesis,” using biomedical research and evolutionary studies to explain how humans evolved to need physical activity, particularly in and after middle age, to increase life span and reduce the risk of disease. (Cooney, 11/22)
Stat: Experts Lay Out How To Keep AI In Health Care In Check
The reach of artificial intelligence in health care settings has expanded to touch everything from cancer care to appointment no-shows. But as AI algorithms transition from exciting proofs-of-concept to a routine part of care, regulators, researchers, and hospital leaders must determine how to keep the technology in check to prevent bias. (Bender, 11/23)
